
FASN Inhibitor – TVB-2640
Indication – NASH
Phase 2
FASN Inhibitor – TVB-2640
Indication – Oncology
Phase 2
FASN Inhibitor – TVB-3567
Indication – Undisclosed
Preclinical
Posters & Publications
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
EClinicalMedicine
Read More